BioCentury
ARTICLE | Clinical News

Ameluz regulatory update

December 30, 2016 1:46 AM UTC

EMA’s CHMP recommended approval of an expanded label for Biofrontera’s Ameluz aminolevulinic acid to include treatment of superficial and/or nodular basal cell carcinoma (BCC) unsuitable for surgical ...

BCIQ Company Profiles

Biofrontera AG (Germany)